Zobrazeno 1 - 10 of 378 pro vyhledávání: '"Machkova, N."'
1
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts
Autor: Lukas, M., Kolar, M., Reissigova, J., Duricova, D., Machkova, N., Hruba, V., Vasatko, M., Jirsa, J., Pudilova, K., Malickova, K.
Originator-adalimumab, an established treatment for patients with Crohn’s disease (CD), showed no difference in efficacy or adverse events versus adalimumab biosimilar SB5 (SB5-adalimumab) over 10 weeks (W) of treatment. To understand the long-term
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c30167d21e848e5fb83f1be910c6775
Zobrazit plný text záznamu
2
Akademický článek
Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
Autor: Cerna K; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; GENNET, Prague, Czech Republic., Duricova D; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Lukas M; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic.; Department of Surgery, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic., Kolar M; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic., Machkova N; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Hruba V; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Mitrova K; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic., Kubickova K; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Kostrejova M; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic., Jirsa J; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Kastylova K; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Peterka S; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Internal Medicine, Hospital Jindrichuv Hradec, Jindrichuv Hradec, Czech Republic., Vojtechova G; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; ResTrial GastroEndo, Prague, Czech Republic., Lukas M; Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Publikováno v: Crohn's & colitis 360 [Crohns Colitis 360] 2023 Jul 25; Vol. 5 (4), pp. otad040. Date of Electronic Publication: 2023 Jul 25 (Print Publication: 2023).
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Autor: Cerna K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; GENNET Prague, Czech Republic., Duricova D; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic., Machkova N; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Hruba V; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Mitrova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic., Kubickova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Kostrejova M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic., Teplan V; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Postgradual Medical Education, Prague, Czech Republic.; Department of Internal Medicine, University Hospital and Medical Faculty, Ostrava, Czech Republic., Vasatko M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Kastylova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2022 Oct 03; Vol. 28 (10), pp. 1506-1512.
Zobrazit plný text záznamu
5
Akademický článek
Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Autor: Cerna K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; GENNET Prague, Czech Republic., Duricova D; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Hindos M; AGILAB Group s.r.o., Prague, Czech Republic., Hindos Hrebackova J; AGILAB Group s.r.o., Prague, Czech Republic., Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic., Machkova N; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Hruba V; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Mitrova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic., Kubickova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Kastylova K; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic., Teplan V; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Postgradual Medical Education, PragueCzech Republic.; Department of Internal Medicine, University Hospital and Medical Faculty, Ostrava, Czech Republic., Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Sep 08; Vol. 16 (9), pp. 1347-1353.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
Autor: Lukas M; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic.; First Medical Faculty, Charles University, Prague, Czech Republic., Kolar M; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Reissigova J; Institute of Computer Science of the Czech Academy of Sciences, Prague, Czech Republic., Duricova D; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Machkova N; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Hruba V; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Lukas M; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Vasatko M; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Jirsa J; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Pudilova K; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic., Malickova K; IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic.; First Medical Faculty, Charles University, Prague, Czech Republic.
Publikováno v: Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2022 Jul; Vol. 57 (7), pp. 814-824. Date of Electronic Publication: 2022 Mar 02.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje